Boston Trust Walden Corp Makes New Investment in LeMaitre Vascular, Inc. $LMAT

Key Points

• Boston Trust Walden opened a new position in LeMaitre Vascular, buying 345,634 shares worth approximately $28.5 million, or about 1.51% of the company.
• Third-quarter revenue rose 11.3% year over year to $67.97 million, slightly ahead of estimates, but earnings per share of $0.65 missed the $0.69 consensus and fell from $0.75 a year earlier.
• Analysts’ average rating is Hold, with a consensus price target of $105.60. LeMaitre also declared a quarterly dividend of $0.25 per share.

Boston Trust Walden Corp purchased a new position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 345,634 shares of the medical instruments supplier's stock, valued at approximately $28,546,000. Boston Trust Walden Corp owned about 1.51% of LeMaitre Vascular as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Bridge City Capital LLC raised its holdings in shares of LeMaitre Vascular by 35.5% in the third quarter. Bridge City Capital LLC now owns 116,980 shares of the medical instruments supplier's stock worth $9,661,000 after acquiring an additional 30,639 shares during the last quarter. ProShare Advisors LLC raised its holdings in LeMaitre Vascular by 36.2% in the 3rd quarter. ProShare Advisors LLC now owns 102,571 shares of the medical instruments supplier's stock valued at $8,471,000 after acquiring an additional 27,270 shares during the last quarter. Flagship Harbor Advisors LLC acquired a new position in LeMaitre Vascular in the 3rd quarter valued at $352,000. Gibbs Wealth Management raised its holdings in LeMaitre Vascular by 6.4% in the 3rd quarter. Gibbs Wealth Management now owns 10,116 shares of the medical instruments supplier's stock valued at $835,000 after acquiring an additional 607 shares during the last quarter. Finally, Sterling Capital Management LLC lifted its stake in shares of LeMaitre Vascular by 844.2% during the 3rd quarter. Sterling Capital Management LLC now owns 727 shares of the medical instruments supplier's stock worth $60,000 after purchasing an additional 650 shares during the period. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on LMAT shares. Seaport Research Partners set a $110.00 price target on LeMaitre Vascular in a research note on Thursday. Wall Street Zen lowered shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Wednesday, August 5th. Citizens Jmp cut their price target on shares of LeMaitre Vascular from $127.00 to $110.00 and set a "market outperform" rating on the stock in a research note on Thursday. Finally, Weiss Ratings lowered shares of LeMaitre Vascular from a "buy (b-)" rating to a "hold (c+)" rating in a report on Friday, October 23rd. Three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $105.60.

LeMaitre Vascular Stock Performance

LMAT stock opened at $83.49 on Friday. LeMaitre Vascular, Inc. has a fifty-two week low of $78.22 and a fifty-two week high of $118.01. The company has a quick ratio of 13.96, a current ratio of 16.31 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $1.91 billion, a P/E ratio of 31.97, a PEG ratio of 2.54 and a beta of 0.51. The company has a 50-day simple moving average of $81.46 and a 200 day simple moving average of $94.14.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.65 earnings per share for the quarter, missing analysts' consensus estimates of $0.69 by ($0.04). The company had revenue of $67.97 million during the quarter, compared to analyst estimates of $67.39 million. LeMaitre Vascular had a net margin of 23.51% and a return on equity of 15.57%. The company's revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.75 EPS. Sell-side analysts predict that LeMaitre Vascular, Inc. will post 2.89 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Thursday, November 19th will be paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Thursday, November 19th. LeMaitre Vascular's dividend payout ratio is presently 35.09%.

Key LeMaitre Vascular News

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q3 revenue rose 11.3% year over year to $67.97 million, beating the $67.39 million consensus. The company also declared a quarterly dividend of $0.25 per share. LeMaitre Q3 2026 Financial Results
• Positive Sentiment: Citizens JMP kept its “market outperform” rating, and Barrington retained “outperform,” signaling both firms still see potential despite reducing their targets. Citizens JMP rating and price target Barrington price target update
• Negative Sentiment: Adjusted earnings were $0.65 per share, below the $0.69 consensus and down from $0.75 a year earlier. The earnings shortfall, alongside a cautious outlook, likely outweighed the revenue beat and contributed to the stock’s decline. LeMaitre Vascular misses Q3 earnings estimates Q3 2026 outlook analysis
• Negative Sentiment: Both firms cut their price targets: Barrington lowered its target to $91 from $95, while Citizens JMP reduced its target to $110 from $127. The cuts suggest more restrained expectations even though the firms kept favorable ratings. Barrington price target update

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a medical device company focused on the treatment of peripheral vascular disease. The company develops, manufactures and markets products used primarily by vascular surgeons and other specialists in open vascular surgery procedures.

Its product portfolio includes biological and synthetic vascular grafts, carotid shunts, embolectomy and thrombectomy catheters, valvulotomes, vessel closure devices, vascular patches and surgical instruments. These products are designed to support procedures involving the arteries and veins, including the repair, reconstruction and treatment of diseased or obstructed blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular sells its products through a combination of direct sales personnel and distributors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.